Willow

The terms identify Willow Health Services, Inc. and a Houston correspondence address; the contact page supplies support and legal email channels. An operator contact telephone has not been established. Pharmacy and government helpline numbers are not treated as Willow's own support number.

Named operator, an attributed physical business address and a working-purpose contact telephone. Distinguish registered or correspondence offices from clinical and dispensing locations; online care does not require a walk-in clinic. Weight: 7.97% (rounded).

The website describes an online assessment reviewed by a U.S. physician, with prescribing dependent on medical appropriateness and patient location. These are published service arrangements; individual clinician credentials and state authorization have not been independently matched.

Who the service is for, prescribing or research-use boundaries, and provider information. Weight: 4.98% (rounded).

The homepage advertises plans starting at $299 per month including the evaluation, medication if prescribed, support and shipping. Terms allow prescription-related fee changes and disclose the final amount at enrollment; the advertised starting price is not a quote for every treatment or dose.

Public prices or a defined quotation process, with recurring or additional charges explained. Weight: 4.98% (rounded).

Terms explain recurring charges, cancellation through the account and restrictions on returning prescription products. They also refer to more specific subscription and return policies. The separate shop's supplement subscription rules are not assumed to govern prescription treatment; exact prescription cancellation and refund cutoffs remain unresolved.

Accessible cancellation, refund or ordering terms and a support channel. Weight: 3.99% (rounded).

Five of the six pharmacy locations disclosed in the terms match current Oklahoma non-resident records by trading name and address. The additional St. George location remains unmatched. These records do not establish every jurisdiction, independent 503A/503B classification or prescription-level assignment.

Named dispensing partners for care services; analytical documentation or manufacturing information for research businesses. Weight: 9.97% (rounded).

Entity-specific legal and regulatory history has not been established from reviewed official records. No clean record or adverse finding is inferred.

Entity/product-specific regulatory notices, enforcement, recalls and their resolution, with dates and jurisdiction. A pharmacy license match alone is not a regulatory-history review. No clean record is inferred from silence. Weight: 9.97% (rounded).

Willow's semaglutide page states that medication batches undergo quality testing. The reviewed statement does not provide a named laboratory, batch identifier or authenticated report. This documents a testing claim, without establishing identity, purity, sterility, potency or the quality of a supplied lot.

Product- and lot-specific laboratory reports covering molecule identity and purity, with the laboratory, report date and issuer authenticity check. Full credit requires independently established laboratory identity and a traceable verified report. A testing policy or a report for another batch provides limited evidence only; purity does not establish sterility, endotoxin control or treatment safety. Weight: 11.96% (rounded).

The official homepage displayed a LegitScript seal linked to the startwillow.com lookup on November 4, 2026. This is a website-seal observation and does not independently confirm current issuer status or product and partner certification.

Checked Nov 4, 2026

Whether the provider displays a LegitScript seal on the reviewed website, with the page and observation date. This is a website disclosure check, not a separate verification of current certification. Inaccessible or mismatched evidence remains unknown; historical issuer checks retain their original scope. Weight: 3.33% (rounded).

The published policy identifies the operator, health-data uses, sharing and privacy contacts, and distinguishes the platform from clinical providers. It refers to separate clinical and pharmacy privacy notices without supplying their links on the reviewed page. Publication does not establish compliance.

Accessible privacy terms identifying the responsible entities, data uses and applicable health-data notice. A HIPAA claim is not independent verification of compliance; HIPAA is not required of every research business. Weight: 5.98% (rounded).

The policy makes general security and testing statements. Specific dated assurance evidence, an independently issued audit and its scope have not been established.

Specific, dated evidence of relevant security practices or an independently issued audit, with its entity, scope and limits. HTTPS, a marketing seal or a claim of being unhackable is insufficient. Weight: 5.98% (rounded).

Terms describe payment authorization and recurring charges; the privacy policy identifies Stripe as a payment processor. This documents billing disclosures, without testing a transaction or certifying payment security or clinical quality.

Disclosed payment processing, billing authorization and recurring-charge arrangements. No processor brand is preferred and a processor does not certify the provider’s clinical or product quality. Weight: 2.99% (rounded).

The site identifies semaglutide and tirzepatide injection and oral-tablet options and describes compounded prescriptions, with state and clinician restrictions. It explicitly distinguishes compounded products from FDA-approved and brand-equivalent medicines. Mentions do not establish current inventory, product quality or patient suitability.

Clear product identity and intended use, distinguishing branded medicines, compounded preparations and research materials; presentation and preparation requirements where relevant. A compounded product is not assumed to be an approved generic. Weight: 7.97% (rounded).

The contact FAQ describes pharmacy processing followed by shipping and warns of possible delays. The safety page differentiates storage for injectable and oral forms. The actual cold-chain process and handling of a temperature excursion have not been established.

Product-specific delivery, temperature and storage instructions, including handling of shipping problems. Refrigeration, freezing or a particular presentation receives no automatic quality bonus. Weight: 4.98% (rounded).

Five partner locations match current Oklahoma non-resident records by trading name and address. Registry names normalize the aliases in Willow's terms, including Red Rock Home Pharmacy at Springville. Absolute 99-6764 is closed and replaced by active 99-10292. The St. George location remains unmatched; these checks do not establish all jurisdictions, sterile-compounding authority, 503A/503B classification or the pharmacy filling a particular prescription.

At least one exactly named dispensing partner matched to an active, unreplaced official state record. This does not verify all partners or all jurisdictions. Weight: 14.95% (rounded).